Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713

Journal of Clinical Oncology

Volumn 22, Issue 1, 2004, Pages 127-132

  Edelman, Martin J ^a   Chansky, Kari ^a   Gaspar, Laurie E ^a   Leigh, Bryan ^a   Weiss, Geoffrey R ^a   Taylor, Sarah A ^a   Crowley, John ^a   Livingston, Robert ^a   Gandara, David R ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; S 9713; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SUBSTITUTION; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 4143093239     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.06.070     Document Type: Article

References (23)

1. McCracken JD, Janaki LM, Crowley JJ, el al: Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma. J Clin Oncol 8:892-898, 1990
2. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11:336-344, 1993
3. Mascauz C, Paesmans M, Berghmans T, et al: A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23-36, 2000
4. Bunn PA, Crowley JJ, Kelly K, et al: Chemoradiotherapy with or without GM-CSF in the treatment of limited stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13:1632-1641. 1995 [Erratum: 13:2860, 1995]
5. Kelly K, Crowley JJ, Bunn PA, et al: The role of recombinant interferon alfa-21 maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: A Southwest Oncology Group study. J Clin Oncol 13:2924-2930, 1995
6. Goodman G, Blasko J, Crowley JJ, et al: Treatment of limited small cell lung cancer with concurrent chemotherapy, radiotherapy, and intensification with high-dose cyclophosphamide: A Southwest Oncology Group pilot study. J Clin Oncol 9:453-457, 1991
7. Edelman MJ, Gandara DR: Small cell lung cancer: Current status of new chemotherapeutic agents. Crit Rev Oncol Hematol 27:211-220, 1998
8. Kelly K, Crowley J, Bunn PA, et al: Randomized phase three trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
9. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346:92-98, 2002
10. Ettinger DS, Finkelstein DM, Sarma RP, et al: Phase II study of paclitaxel in patients with extensive disease small cell lung cancer. An Eastern Cooperative Oncology Group Study. J Clin Oncol 13:1430-1435, 1995
11. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
12. Groen HJ, Fokkema E, Biesma B, et al: Paclitaxel and carboplatin in the treatment of small-cell lung cancer patietns resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross resistant schedule. J Clin Oncol 17:927-932, 1999
13. Gridelli C, Manzione L, Perrone F, et al: Carboplatin plus paclitaxel in extensive small cell lung cancer: A multicentre phase 2 study. Br J Cancer 84:38-41, 2001
14. Thomas P, Castelnau O, Paillotin D, et al: Phase II trial of paclitaxel and carboplatin in metastatic small cell lung cancer: A Groupe Francais de Pneumo-Cancerologie study. J Clin Oncol 19:1320-1325, 2001
15. Kakolyris S, Mavroudis D, Tsavaris N, et al: Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study. Ann Oncol 12:193-197, 2001
16. Ettinger DS, Seiferheld WF, Abrams RA, et al: Cisplatin, etoposide, paclitaxel and concurrent hyperfractionated radiotherapy for patients with limited disease camall cell lung cancer: Preliminary results of RTOG 96-09. Proc Am Soc Clin Oncol 20:490a, 2000 (abstr 1915)
17. Sandier A, Declerk L, Wagner H, et al: A phase Il study of cisplatin plus etoposide plus paclitaxel and concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): An Eastern Cooperative Oncology Group Trial. Proc Am Soc Clin Oncol 20:491a, 2000 (abstr 1920)
18. Niell HB, Herndon JE, Miller AA, et al: Randomized phase III intergroup trial (CALGB 9732) of etoposide and cisplatin with or without paclitaxel and G-CSF in patients with extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 21:293a, 2002 (abstr 1169)
19. Reck M, von Pawel J, Macha HN, et al: Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95:1118-1127, 2003
20. Turrisi AT, Kim Kyungmann K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
21. Albain K, Crowley J, LeBlanc M, et al: Determinants of improved outcome in small-cell lung cancer: An analysis of the 2,580 patient Southwest Oncology Group database. J Clin Oncol 8:1563-1574, 1990
22. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
23. Mori K, Kubota K, Nishiwaki Y, et al: Cisplatin and etoposide plus concurrent hyperfractionated thoracic radiotherapy followed by three cycles of irinotecan and cisplatin for the treatment of limited-stage small cell lug cancer: Updated results: JCOG 9903-D1. Proc Am Soc Clin One 21:294a, 2002 (abstr 1173)